Edit |   |
---|---|
Antigenic Specificity | CD158b2 (KIR2DL3), Human |
Clone | REAL145 |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | n/a |
Format | allophycocyanin (APC) conjugate |
Size | 30 tests in 60 µL |
Concentration | 1:50 |
Applications | Flow cytometry |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | CD158b2 (KIR2DL3) Antibody, anti-human, APC, REAlease®. Clone REAL145 is an antibody fragment derived from the full CD158b2 (KIR2DL3) antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity. | Clone REAL145 recognizes CD158b2 (KIR2DL3), a killer-cell immunoglobulin-like inhibitory receptor (KIR). Expressed by natural killer and a subset of T cells, KIR family of receptors are transmembrane glycoproteins and interact with MHC class I molecules. This interaction allows the KIR receptors to modulate the killing function of cells bearing them. The KIR proteins are categorized by the number of extracellular immunoglobulin domains (2D or 3D) and by the length (long (L) or short (S)) of the cytoplasmic domain. KIR proteins with the long cytoplasmic domain, such as CD158b2, transduce inhibitory signals via an immune tyrosine-based inhibitory motif (ITIM). | The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes. |
Immunogen | n/a |
Other Names | KIR2DL3, Killer cell immunoglobulin-like receptor 2DL3 |
Gene, Accession # | n/a |
Catalog # | 130-115-291 |
Price | $164 |
Order / More Info | CD158b2 (KIR2DL3), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Keaney, L. et al. (2004) Investigation of killer cell immunoglobulin-like receptor gene diversity III. KIR2DL3. Tissue Antigens 64 (2): 188-194. | Gendzekhadze, K. et al. (2009) Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands. Proc. Natl. Acad. Sci. U.S.A. 106: 18692-18697. |